Cefpodoxime - Revision history

Danbot: Remove disease-specific entries now covered by AntibioticDose (4 sections)

2026-03-20T11:08:09Z

Remove disease-specific entries now covered by AntibioticDose (4 sections)

← Older revision		Revision as of 11:08, 20 March 2026
Line 7:		Line 7:

	==Adult Dosing==		==Adult Dosing==
	~~===[[Bronchitis]] (chronic)===~~
	*200mg q 12 h for 10 days
	~~===[[Pharyngitis]]/Tonsillitis===~~
	*100mg q 12 h for 5-10 days
	~~===Skin and soft tissue infection===~~
	*400mg q 12 h for 14 days
	~~===[[Urinary tract infection]], uncomplicated===~~
	*100mg q 12 h for 7 days
	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]		{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]

Danbot: Remove disease-specific dosing covered by dynamic SMW tables

2026-03-20T02:57:49Z

Remove disease-specific dosing covered by dynamic SMW tables

← Older revision		Revision as of 02:57, 20 March 2026
Line 8:		Line 8:
	==Adult Dosing==		==Adult Dosing==
	===[[Bronchitis]] (chronic)===		===[[Bronchitis]] (chronic)===
	*200mg q 12 h for 10 days
	~~===Acute bacterial infection===~~
	*200mg q 12 h for 10 days		*200mg q 12 h for 10 days
	===[[Pharyngitis]]/Tonsillitis===		===[[Pharyngitis]]/Tonsillitis===
	*100mg q 12 h for 5-10 days		*100mg q 12 h for 5-10 days
	~~===Acute community acquired [[pneumonia]]===~~
	*200mg q 12 h for 14 days
	~~===Acute rhino [[sinusitis]]===~~
	*200mg q 12 h for 10 days
	===Skin and soft tissue infection===		===Skin and soft tissue infection===
	*400mg q 12 h for 14 days		*400mg q 12 h for 14 days
	===[[Urinary tract infection]], uncomplicated===		===[[Urinary tract infection]], uncomplicated===
	*100mg q 12 h for 7 days		*100mg q 12 h for 7 days
	~~===[[Pyelonephritis]]===~~
	*200mg q12 for 10 days


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]		{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]

Danbot: Restore original dosing content alongside dynamic SMW tables

2026-03-20T02:37:37Z

Restore original dosing content alongside dynamic SMW tables

← Older revision		Revision as of 02:37, 20 March 2026
Line 7:		Line 7:

	==Adult Dosing==		==Adult Dosing==
			===[[Bronchitis]] (chronic)===
			*200mg q 12 h for 10 days
			===Acute bacterial infection===
			*200mg q 12 h for 10 days
			===[[Pharyngitis]]/Tonsillitis===
			*100mg q 12 h for 5-10 days
			===Acute community acquired [[pneumonia]]===
			*200mg q 12 h for 14 days
			===Acute rhino [[sinusitis]]===
			*200mg q 12 h for 10 days
			===Skin and soft tissue infection===
			*400mg q 12 h for 14 days
			===[[Urinary tract infection]], uncomplicated===
			*100mg q 12 h for 7 days
			===[[Pyelonephritis]]===
			*200mg q12 for 10 days


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]		{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]
	\|?Treats disease=Disease		\|?Treats disease=Disease
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|format=table		\|format=table
	\|limit=50		\|limit=50
	\|mainlabel=-		\|mainlabel=-
	\|headers=show		\|headers=show
	\|sort=Treats disease		\|sort=Treats disease
	}}		}}

	==Pediatric Dosing==		==Pediatric Dosing==
			===General===
			*Infant ≥2 months to children <12 years: 10mg/kg/day (maximum 200mg/dose) q 12 h
			*Children >12 years to adolescent: 100 to 400mg q 12 h
			===Specific indication===
			*[[Bronchitis]] (chronic), acute bacterial infection
			**Adult dosing for Infant ≥2 months to children <12 years
			*[[Acute otitis media]]
			Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 5 days, duration according to AAP recommendation <ref>Lieberthal A. et al.The Diagnosis and Management of Acute Otitis Media.Pediatrics Mar 2013, 131 (3) e964-e999</ref>: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course
			*[[Pharyngitis]]/tonsillitis:
			**Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100mg/dose) q 12 h for 5-10 days
			**Children >12 years to adolescent: adult dosing
			*Acute [[sinusitis]]
			**Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) <ref>Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112</ref>
			**Children >12 years to adolescent: adult dosing
			*Skin soft tissue infection and uncomplicated [[urinary tract infection]]
			**Children >12 years to adolescent: adult dosing


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Pediatric]]		{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Pediatric]]
	\|?Treats disease=Disease		\|?Treats disease=Disease
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|format=table		\|format=table
	\|limit=50		\|limit=50
	\|mainlabel=-		\|mainlabel=-
	\|headers=show		\|headers=show
	\|sort=Treats disease		\|sort=Treats disease
	}}		}}

Danbot: Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

2026-03-20T01:52:24Z

Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

← Older revision		Revision as of 01:52, 20 March 2026
Line 7:		Line 7:

	==Adult Dosing==		==Adult Dosing==
	===~~[[Bronchitis]] (chronic)~~===		===Indications by Disease===
	*200mg q 12 h for 10 days		{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]
	~~===Acute bacterial infection===~~		\|?Treats disease=Disease
	*200mg q 12 h for 10 days		\|?Has Dose=Dose
	~~===~~[[~~Pharyngitis~~]]~~/Tonsillitis===~~		\|?Has Context=Context
	*100mg q 12 h for 5-10 days		\|format=table
	~~===Acute community acquired~~ [[~~pneumonia~~]]===		\|limit=50
	*200mg q 12 h for 14 days		\|mainlabel=-
	=~~==Acute rhino [[sinusitis]]===~~		\|headers=show
	*200mg q 12 h for 10 days		\|sort=Treats disease
	=~~==Skin and soft tissue infection===~~		}}
	*400mg q 12 h for 14 days
	=~~==[[Urinary tract infection]], uncomplicated===~~
	*100mg q 12 h for 7 days
	=~~==[[Pyelonephritis]]===~~
	*200mg q12 for 10 days

	==Pediatric Dosing==		==Pediatric Dosing==
	===~~General~~===		===Indications by Disease===
	*Infant ≥2 months to children <12 years: ~~10mg/kg/day (maximum 200mg/dose) q 12 h~~		{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Pediatric]]
	*Children >12 years to adolescent: 100 to 400mg q 12 h		\|?Treats disease=Disease
	~~===Specific indication===~~		\|?Has Dose=Dose
	*[[~~Bronchitis~~]] ~~(chronic), acute bacterial infection~~		\|?Has Context=Context
	**Adult dosing for Infant ≥2 months to children <12 years		\|format=table
	*[[~~Acute otitis media~~]]		\|limit=50
	Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 5 days, duration according to AAP recommendation <ref>Lieberthal A. et al.The Diagnosis and Management of Acute Otitis Media.Pediatrics Mar 2013, 131 (3) e964-e999</ref>: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course		\|mainlabel=-
	*[[Pharyngitis]]/tonsillitis:		\|headers=show
	**Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100mg/dose) q 12 h for 5-10 days		\|sort=Treats disease
	**Children >12 years to adolescent: adult dosing		}}
	*Acute [[sinusitis]]
	**Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) <ref>Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112</ref>
	**Children >12 years to adolescent: adult dosing
	*Skin soft tissue infection and uncomplicated [[urinary tract infection]]
	**Children >12 years to adolescent: adult dosing

	==Special Populations==		==Special Populations==

Masoodrm: /* General */

2025-12-10T18:24:16Z

General

← Older revision		Revision as of 18:24, 10 December 2025
Line 4:		Line 4:
	*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL		*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL
	*Routes of Administration: PO		*Routes of Administration: PO
	*Common Trade Names: Cefopodoxine Proxetil~~, Vantin~~		*Common Trade Names: Vantin, Cefopodoxine Proxetil

	==Adult Dosing==		==Adult Dosing==

Ostermayer: /* Contraindications */

2025-07-18T18:18:06Z

Contraindications

← Older revision		Revision as of 18:18, 18 July 2025
Line 56:		Line 56:
	*Allergy to class/drug		*Allergy to class/drug
	*Caution:		*Caution:
	**Hypersensitivity to [[penicillin]		**Hypersensitivity to [[penicillin]]
	**Renal impairment		**Renal impairment
	**Concurrent nephrotoxic agent		**Concurrent nephrotoxic agent

Ostermayer at 16:19, 18 July 2025

2025-07-18T16:19:29Z

← Older revision		Revision as of 16:19, 18 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type: 3rd generation [[Is DrugClass::cephalosporin]]		*Type: [[Is Generation::3rd generation]] [[Is DrugClass::cephalosporin]]
	*Dosage Forms: tablet, oral suspension		*Dosage Forms: tablet, oral suspension
	*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL		*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL

Ostermayer at 14:47, 18 July 2025

2025-07-18T14:47:58Z

← Older revision		Revision as of 14:47, 18 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type: 3rd generation [[cephalosporin]]		*Type: 3rd generation [[Is DrugClass::cephalosporin]]
	*Dosage Forms: tablet, oral suspension		*Dosage Forms: tablet, oral suspension
	*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL		*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL

Ostermayer: /* Urinary tract infection, uncomplicated */

2025-06-23T00:28:15Z

Urinary tract infection, uncomplicated

← Older revision		Revision as of 00:28, 23 June 2025
Line 21:		Line 21:
	===[[Urinary tract infection]], uncomplicated===		===[[Urinary tract infection]], uncomplicated===
	*100mg q 12 h for 7 days		*100mg q 12 h for 7 days
			===[[Pyelonephritis]]===
			*200mg q12 for 10 days

	==Pediatric Dosing==		==Pediatric Dosing==

ClaireLewis at 21:57, 19 September 2019

2019-09-19T21:57:02Z

← Older revision		Revision as of 21:57, 19 September 2019
Line 94:		Line 94:
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:ID]]